Foamix Pharmaceuticals its gathering the attention of investors around the reporting of worse than expected earnings with an EPS of -0.35, representing -2.94% of the forecasted. The company also announced the Merging with Menlo Therapeutics (MNLO) focused on the development and commercialization of therapeutics for dermatologic indications. These news can imply an increase in volatility on the asset and further investors' especulation.
As informações e publicações não devem ser e não constituem conselhos ou recomendações financeiras, de investimento, de negociação ou de qualquer outro tipo, fornecidas ou endossadas pela TradingView. Leia mais em Termos de uso.